临床试验/NCT00195286

NCT00195286已完成不适用

Study of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections.

Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 180 人开始时间: 2004年6月最近更新: 2009年9月25日

适应症

相关药物

试验速览

阶段: 不适用
状态: 已完成
发起方
入组人数: 180

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections

研究设计

研究类型: Observational
观察模型: Case Only
时间视角: Prospective

入排标准

年龄范围: 16 Years 至 —（Child, Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Hospitalized patients over 16 years of age with complicated urinary infection produced by bacteria that are suspected to be susceptible to treatment with Piperacillin-tazobactam.

排除标准

•Patients known, or thought to be hypersensitivity to beta-lactams
•Patients with an uncomplicated urinary tract infection

研究者

发起方

Wyeth is now a wholly owned subsidiary of Pfizer

申办方类型

Industry

相似试验

Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas AeruginosaPseudomonas Aeruginosa Infection

NCT01577368Fundación Pública Andaluza para la gestión de la Investigación en Sevilla76

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology UnitsGram-Positive Bacterial InfectionsEscherichia Coli InfectionsKlebsiella Infections

NCT00167999Wyeth is now a wholly owned subsidiary of Pfizer200

进行中（未招募）

Eficacia y seguridad de Piperacilina/Tazobactam administrada en perfusión continua versus infusión intermitente en pacientes con infección complicada o nosocomial con sospecha o aislamiento de Pseudomonas aeruginosa.infecciones complicadas o de origen nosocomial con sospecha o aislamiento de Pseudomonas aeruginosaMedDRA version: 13Level: LLTClassification code 10021860Term: Infección por Pseudomonas aeruginosa

EUCTR2010-024606-34-ESMª Victoria Gil Navarro

PK of Piperacillin/Tazobactam in Adults Undergoing ECMOAcute Respiratory Failure With Hypoxia

NCT03467854Columbia University10

Tazocin Intervention StudyBacterial Infections

NCT00478855Wyeth is now a wholly owned subsidiary of Pfizer500